Saponin for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Saponin may be beneficial for
COVID-19 according to the studies below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed saponin in detail.
, Tumor Necrosis Factor-Alpha (TNF- α) and Antiviral Activities of Artemisia SPP. Extracts on SARS-COV2, Rwanda Journal of Medicine and Health Sciences, doi:10.4314/rjmhs.v8i2.2
BackgroundThe challenges posed by Coronavirus disease 2019 (COVID-19), including treatment resistance, pandemic threats, and vaccine failure, necessitate the need for locally sourced efficacious therapeutic interventions. We investigated the in-vitro antiviral effects of natural medicinal compounds from Artemisia spp., validated by molecular docking, on TNF-α levels in hospitalized SARS-CoV-2 patients from a designated Lagos COVID-19 isolation centre.MethodsBioactive chemicals in ethanol and dichloromethane (DCM) extracts from freshly collected, dried, and powdered A. afra and A. annua leaves were characterised using UHPLC. A cross-sectional study of 253 hospitalised SARS-CoV-2 patients was conducted to evaluate the extracts' antiviral activity through serum TNF-α modulation; and docking techniques to determine compound-TNF-α binding affinities.ResultsPhytochemical screening of A. annua revealed therapeutic constituents ((lactones, monoterpenes, flavonoids, and sesquiterpenes (artemisinin, rutin, and phenolic acids)) confirmed by UHPLC. The dichloromethane extract of A. afra demonstrated greater TNF-α inhibition in critically ill COVID-19 patients unlike ethanol extracts. Molecular docking validated TNF-α binding affinity for most isolated compounds. ConclusionsArtemisia spp. promises antiviral-proinflammatory cytokine regulation, justifying clinical COVID-19 prophylaxis/therapeutic research, especially against resistant SARS-CoV-2 variants. This could reduce vaccination dependency in impoverished nations while addressing vaccine efficacy and local immunity gaps.Rwanda J Med Health Sci 2025;8(2):181-197